Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease

被引:13
|
作者
Colao, A
Pivonello, R
Ferone, D
Faggiano, A
Facciolli, G
Di Somma, C
Boudouresque, F
Oliver, C
Lombardi, G
机构
[1] Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, I-80131 Naples, Italy
[2] INSERM, U297, Lab Expt Neuroendocrinol, Marseille, France
关键词
D O I
10.1046/j.1365-2265.1998.00479.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To evaluate the effect of CRH administration on plasma AVP and ANF concentration in patients with Cushing's disease and healthy subjects. SUBJECTS Fifteen patients with Cushing's disease and 15 sex- and age-matched healthy subjects entered the study. STUDY DESIGN All subjects were randomly given iv, 100 mu g hCRH and placebo (NaCl 0.9%) on two non consecutive days. Blood samples for plasma AVP and ANF assay were taken before and every 15 min for 2hr after CRH or placebo. Five out of the 15 patients with Cushing's disease underwent a repeat CRH test after surgical cure of the disease, RESULTS At baseline evaluation, plasma ANF concentrations were significantly higher in patients with Cushing's disease compared to healthy subjects (15.0+/-0.8 vs 10.8+/-0.6pmol/l, P<0.001) whereas plasma AVP concentrations were similar between the two groups of subjects (8 .0+/-0.4 vs 6.8+/-0 6 pmol/l), CRH administration induced a significant increase in plasma ANF concentrations both in patients with Cushing's disease (24.0 +/- 6pmol/l, P<0.05) and healthy subjects (29.4+/-1.5pmol/l, P<0. 05). Conversely, a significant increase in plasma AVP concentrations was found only patients with Cushing's disease (24 .0 il 4 vs 8 0 i 0.4pmol/l, P<0 05). In addition, patients with Cushing's disease had an increase in ANF levels after CRH significantly lower than that observed in healthy subjects (peak/basal ratio: 1.7 +/- 0 1 vs 3 1 i 0 4, P<0 01). In 5 patients re-tested after disease cure, CRH administration significantly increased plasma ANF levels (26.8+/-1 1 vs 10.7+/-0 4pmol/l, P<0 05) but it did not modify plasma AVP levels (8 4+/-0 4 vs 7 3+/- 0.5pmol/l). ANF response to CRH in patients cured from Cushing's disease was similar to that recorded in healthy subjects (peak/basal ratio: 2.6+/-0 2 vs 3 1 i 0 4). CONCLUSION CRH stimulates ANF secretion both in patients with Cushing's disease and healthy subjects. Plasma ANF response to CRH is blunted in patients with Cushing's disease compared to patients cured from Cushing's disease and healthy subjects, probably because of hypercortisolism. By contrast, CRH stimulates AVP secretion only in patients with Cushing's disease, but not in patients cured from Cushing's disease and healthy subjects. This phenomenon could be related to the activity of the disease.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 50 条
  • [21] Paraneoplastic Cushing syndrome because of corticotrophin-releasing hormone-secreting Wilms' tumor
    Wang, Jingfu
    Zhang, Guangchao
    JOURNAL OF PEDIATRIC SURGERY, 2008, 43 (11) : 2099 - 2101
  • [22] EFFECT OF ACETYLCHOLINE AND 5-HYDROXYTRYPTAMINE ON THE SECRETION OF CORTICOTROPHIN-RELEASING FACTOR-41 AND ARGININE VASOPRESSIN FROM THE RAT HYPOTHALAMUS INVITRO
    HILLHOUSE, EW
    MILTON, NGN
    JOURNAL OF ENDOCRINOLOGY, 1989, 122 (03) : 713 - 718
  • [23] The effect of growth hormone secretagogues on the release of growth hormone-releasing hormone, somatostatin, vasopressin, and corticotrophin-releasing hormone from the rat hypothalamus in vitro
    Korbonits, M
    Little, JA
    Trainer, PJ
    Besser, M
    Grossman, A
    Forsling, ML
    Costa, A
    Tringali, G
    Navarra, P
    GROWTH HORMONE SECRETAGOGUES IN CLINICAL PRACTICE, 1998, : 231 - 249
  • [24] SEPARATION OF GROWTH HORMONE-RELEASING FACTOR (GHRF) FROM CORTICOTROPHIN-RELEASING FACTOR (CRF)
    DHARIWAL, AP
    ANTUNESR.J
    KRULICH, L
    MCCANN, SM
    NEUROENDOCRINOLOGY, 1965, 1 (06) : 341 - &
  • [25] STUDIES ON THE RESPONSIVENESS OF THE ANTERIOR-PITUITARY GLAND AFTER PRIMING WITH CORTICOTROPHIN-RELEASING FACTOR (CRF) OR ARGININE VASOPRESSIN (AVP)
    BRANAGAN, L
    GILLHAM, B
    JONES, M
    REGULATORY PEPTIDES, 1983, 7 (03) : 278 - 278
  • [26] ARGININE VASOPRESSIN ABOLISHES THE DIURETIC EFFECT OF ATRIAL NATRIURETIC FACTOR IN MAN
    MCMURRAY, J
    STRUTHERS, AD
    BRITISH HEART JOURNAL, 1988, 59 (05): : 627 - 627
  • [27] EFFECT OF NORADRENALINE AND GAMMA-AMINOBUTYRIC ACID ON THE SECRETION OF CORTICOTROPHIN-RELEASING FACTOR-41 AND ARGININE VASOPRESSIN FROM THE RAT HYPOTHALAMUS INVITRO
    HILLHOUSE, EW
    MILTON, NGN
    JOURNAL OF ENDOCRINOLOGY, 1989, 122 (03) : 719 - 723
  • [28] Corticotrophin-releasing activity of desmopressin in Cushing's disease:: lack of correlation between in vivo and in vitro responsiveness
    Giraldi, FP
    Marini, E
    Torchiana, E
    Mortini, P
    Dubini, A
    Cavagnini, F
    JOURNAL OF ENDOCRINOLOGY, 2003, 177 (03) : 373 - 379
  • [29] The anorexic effect of alpha-melanocyte-stimulating hormone is mediated by corticotrophin-releasing factor in chicks
    Tachibana, Tetsuya
    Oikawa, Daichi
    Takahashi, Hirokazu
    Boswell, Tim
    Furuse, Mitsuhiro
    COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR & INTEGRATIVE PHYSIOLOGY, 2007, 147 (01): : 173 - 178
  • [30] Vasopressin, oxytocin, corticotrophin-releasing factor, and sodium responses during fluoxetine administration in the rat
    Isam E. Marar
    Janet A. Amico
    Endocrine, 1998, 8 : 13 - 18